Treatment of Newly Diagnosed Peripheral T-cell Lymphoma

Z

Zhengzhou University

Status and phase

Unknown
Phase 4

Conditions

Newly Diagnosed Peripheral T-cell Lymphoma

Treatments

Drug: CHOP Regimen
Drug: Apatinib

Study type

Interventional

Funder types

Other

Identifiers

NCT03631862
hnslblzlzx2018-5

Details and patient eligibility

About

The purpose of this study is to evaluate the efficacy and safety of Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Full description

Patients with peripheral T-cell lymphoma usually have a bad prognosis. These patients cannot be treated successfully with the conventional CHOP regimen. Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. The investigators have been proceeding this trial to evaluate the efficacy and safety of the Apatinib Combined With CHOP Regimen(cyclophosphamide, vincristine, epirubicin, prednisone in the treatment of newly diagnosed peripheral T-cell lymphoma.

Enrollment

100 estimated patients

Sex

All

Ages

14 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age range 14-70 years old; ECOG performance status 0-2.
  • Estimated survival time > 6 months.
  • Histological confirmed Peripherial T-cell lymphoma.
  • Have taken no treatment.
  • None of chemotherapy contraindication: hemoglobin ≥ 90 g/dl, neutrophil ≥ 1.5×109/L, platelet ≥ 100×109/L, ALT and AST ≤ 2×ULN, serum bilirubin ≤ 1.5×ULN, serum creatine ≤ 1.5×upper limitation of normal (ULN), Serum Albumin ≥ 30g/L, serum plasminogen is normal.
  • At least one measurable lesion.
  • None of other serious diseases, cardiopulmonary function is normal.
  • Pregnancy test of women at reproductive age must be negative.
  • Patients could be followed up.
  • None of other relative treatments including the traditional Chinese medicine, immunotherapy, biotherapy except anti-bone metastasis therapy and other symptomatic treatments.
  • Volunteers who signed informed consent.

Exclusion criteria

  • Patients with contraindications (active bleeding, ulcers, intestinal perforation, intestinal obstruction, 30 days after major surgery, hypertension uncontrollable drugs, grade III-IV cardiac insufficiency, severe liver and kidney dysfunction);
  • Abnormal coagulation (INR > 1.5 or prothrombin time (PT) > ULN + 4 seconds or APTT > 1.5 ULN), with bleeding tendency or undergoing thrombolysis or anticoagulant therapy;
  • Urine routine indicates urinary protein ≥ ++, or confirmed 24-hour urine protein ≥ 1.0 g;
  • Disagreement on blood sample collection.
  • Patients allergic of any of drug in this regimen or with metabolic disorder.
  • Pregnant or lactating women.
  • Serious medical illness likely to interfere with participation.
  • Serious infection.
  • Primitive or secondary tumors of central nervous system.
  • Chemotherapy or radiotherapy contraindication.
  • The evidence of CNS metastasis.
  • History of peripheral nervous disorder or dysphrenia.
  • Patients participating in other clinical trials.
  • Patients taking other antitumor drugs.
  • Patients estimated to be unsuitable by investigator.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

100 participants in 2 patient groups

Apatinib combined with CHOP regimen
Experimental group
Description:
Apatinib: 250mg/d d1-21 po CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) : Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
Treatment:
Drug: Apatinib
Drug: CHOP Regimen
CHOP regimen
Experimental group
Description:
CHOP regimen(Cyclophosphamide,Vincristine,Epirubicin,Prednisone) : Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Epirubicin,60mg/m2,ivgtt,d1;Prednisone 60mg/m2,po, d1-5
Treatment:
Drug: CHOP Regimen

Trial contacts and locations

1

Loading...

Central trial contact

Mingzhi Zhang, Pro,Dr

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems